HONGENE BIOTECH

Live / Registered — Registered (as of 05 May 2026)

What this means for you

Registered since 05 May 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 05 May 2032: the §8 declaration of use).

Record

Serial number
98544404
Registration number
8244538
Mark type
Design + words
Filed
10 May 2024
Published for opposition
11 Mar 2025
Registered
05 May 2026
Next maintenance filing
§8 declaration of use, due by 05 May 2032 (grace period to 05 Nov 2032)
Attorney of record
Michael T. Smith

Goods and services

  • Class 001 — Chemicals: adjuvants, other than for medical or veterinary purposes; bases in the nature of alkalies being chemical preparations; biochemical catalysts; biological preparations for use in industry and science, other than for medical or veterinary purposes; carbonic hydrates; biochemical catalysts; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purposes; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; diagnostic preparations for research laboratory use; diagnostic preparations, other than for medical or veterinary purposes; enzyme preparations for industrial purposes; enzymes for industrial purposes; ferments for chemical purposes, namely, fermentation extract; glucose for industrial purposes, namely, glucosides; industrial chemicals; isotopes for industrial purposes preparations of microorganisms, other than for medical and veterinary use; salts being chemical preparations; sulfides
  • Class 005 — Pharmaceuticals: biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; biological preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; capsules sold empty for medicines; chemical preparations for medical purposes for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for pharmaceutical purposes; chemical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for veterinary purposes; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease; diagnostic biomarker reagents for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; diagnostic preparations for veterinary purposes; drugs being pharmaceutical preparations for treatment and prevention of ocular disease, cerebral disease, central nervous system disease, cardiovascular disease and metabolic disease for medical purposes; enzyme preparations for medical purposes; enzyme preparations for veterinary purposes; enzymes for medical purposes; enzymes for veterinary purposes; ferments for pharmaceutical purposes; immunostimulants; isotopes for medical purposes; medical preparations for slimming purposes; medicinal hair growth preparations; medicines for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss for human purposes; medicines for veterinary purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceutical preparations for treatment and prevention cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; pharmaceuticals for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; phosphates for pharmaceutical purposes for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss; preparations of microorganisms for medical or veterinary use; vaccines; veterinary preparations for treatment and prevention of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection, obesity, hair loss

Owner

Prosecution history

  • 05 May 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 05 May 2026 — REGISTERED-PRINCIPAL REGISTER
  • 15 Apr 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 15 Apr 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 14 Apr 2026 — STATEMENT OF USE PROCESSING COMPLETE
  • 06 Nov 2025 — USE AMENDMENT FILED
  • 06 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
  • 13 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 13 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 13 May 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 06 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 11 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 11 Mar 2025 — PUBLISHED FOR OPPOSITION
  • 05 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 14 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER

View this trademark record on Rightsy